The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: Establishment of reference ranges in a large population of healthy men

British Journal of Urology

Volumn 82, Issue 2, 1998, Pages 231-236

  Lein, M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Free PSA; Prostate specific antigen; Reference range; Tumour marker

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGE; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CLINICAL EXAMINATION; COHORT ANALYSIS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REFERENCE VALUE; TRANSRECTAL ULTRASONOGRAPHY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; ENZYME TESTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES;

EID: 0031821333     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00723.x     Document Type: Article

References (29)

1. Landis SH, Murray T. Bolden S et al. Cancer statistics 1998. ÇA Cancer] Clin 1998: 48: 6-29
2. American Urological Association. Early detection of prostate cancer and use of transrectal ultrasound. In American Urological Association 1992 Policy Statement Book. Baltimore: American Urological Association; 1992: 4.20
3. Stamey TA. Yang N. Hay AR, McNeal JE, Freiha FS. Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Eng] J Med 1987: 317: 909-16
4. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991: 145: 907-23
5. Bostwick DG. Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer. Am }Clin Pathol 1994: 102: S31-7
6. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. ] Urol 1989; 142: 1007-11
7. Oesterling JE. Prostate-specific antigen: improving its ability to diagnose early prostate cancer. JAMA 1992: 267: 2236-8
8. Armbruster DA. Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 1993; 39: 181-95
9. Lange PH, Ercole CJ. Lightner DJ. Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141: 873-9
10. Bunting PS. A guide to the interpretation of serum prostate specific antigen levels. Clin Biochem 1995; 28: 221-41
11. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817-21
12. Carter HB. Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20
13. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostatespecific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4
14. Lilja H. Christensson A, Dahlen U et al. Prostate specific antigen in human serum occurs predominately in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37: 1618-25
15. Stenman UH. Leinonen J. Alfthan H, Rannikko S, Tuhkanen K, Alfthan 0. A complex between prostate specific antigen and alpha 1-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6
16. Stamey TA. Chen Z, Prestigiacomo A. Serum prostate specific antigen binding alpha 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994: 152: 1510-4
17. Christensson A. Björk T, Nilsson 0 et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-5
18. Jung K, Stephan C. Lein M et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996; 42: 1026-33
19. Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20
20. Catalona WJ, Smith DS. Comparison of different serum prostate specific antigen measures for early prostate cancer detection. Cancer 1994; 74: 1516-8
21. Bjartell A. Björk T, Matikainen MT, Abrahamsson PA. di Sant'Agnese A, Lilja H. Production of alpha 1-antichymotrypsin by PSA-containing cells of the human prostate epithelium. Urology 1993; 42: 502-10
22. Björk T, Bjartell A, Abrahamsson PA. Hulkko S. di Sant'Agnese A. Lilja H. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994; 43: 427-34
23. Huber PR, Schmid HP, Mattarelli G, Strittmatter B. Vansteenbrugge GJ, Maurer A. Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate. Prostate 1995; 27: 212-9
24. DeAntoni EP, Crawford ED. Oesterling JE et al. Age-and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 1996: 48: 234-9
25. Anderson JR, Strickland D, Corbin D. Byrnes JA, Zweiback E. Age-specific reference ranges for serum prostate-specific antigen. Urology 1995; 46: 54-7
26. Bangma CH, Rietbergen JEW, Kranse R. Blijenberg BG, Petterson K. Schroeder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997; 157: 2191-6
27. Semjonow A. Oberpenning F, Brandt B. Zechel C, Brandau W, Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostatespecific antigen. Urology 1996; 48: 10-5
28. Catalona WJ, Smith DS. Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/mL and benign prostate examination. JAMA 1997; 277: 1452-5
29. Oesterling JE. Jacobsen SJ, Klee GG et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995: 154: 1090-5